TET2 remains the most frequently mutated or deleted TET member in a variety of hematological malignancies, and approximately 15% of individuals with myeloid malignancies harbor a mutation or deficiency in TET2, which correlates with disease progression (Delhommeau et al. 2009). This evidence concerns the gene TET2 and myeloid neoplasm.